直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB: What to Expect on Remand

December 22, 2016

Authored and Edited by Anthony A. Hartmann; James D. Stein

Only a portion of Federal Circuit decisions on appeals from IPRs and CBMs have remanded the cases in full or in part to the Patent Trial and Appeal Board (“PTAB”). These remanded cases have been working their way through the PTAB, leading to new final written decisions.

While there are rules and statutes governing the timing of the trial phase of a PTAB proceeding, there are no such rules governing the remand process. Thus, a review of the PTAB docket is needed to determine what a party can expect on remand. While the procedures used on remand can be panel-specific, there are some similarities.

Teleconference with the Board

Jurisdiction returns to the PTAB upon issuance of the Federal Circuit’s mandate. See Federal Circuit Rule 41. A teleconference with the PTAB may occur within a week to about a month after the mandate issues. While most orders do not indicate whether a party requested the teleconference, one order commented that no teleconference occurred because the parties failed to request one. adidas AG v. NIKE, Inc., IPR2013-00067 (Aug. 10, 2016) (Paper 62). While they are common, a teleconference does not always occur. See, e.g., Corning Optical Comm’ns RF, LLC v. PPC Broadband, Inc., IPR2013-00340 (May 20, 2016) (Paper 82) (without a prior teleconference, the PTAB issued an order to confer to determine whether supplemental briefing was necessary).

Briefing on Remand

The PTAB typically authorizes the parties to submit five- to 15-page briefs explaining the impact of the Federal Circuit’s ruling. But the Board has twice denied briefing following a request and has once decided not to authorize briefing when no party had made a request. See, e.g., Corning Optical Comm’ns RF, LLC v. PPC Broadband, Inc., IPR2013-00340 (May 20, 2016) (Paper 85); adidas AG v. NIKE, Inc., IPR2013-00067 (Aug. 10, 2016) (Paper 62).

Simultaneous briefing by the petitioner and the patent owner is common. See, e.g., Shaw Indus. Group, Inc. v. Automated Creel Sys., Inc., IPR2013-00132 (June 3, 2016) (Paper 49) at 4 (“We are not persuaded that Petitioner should file its brief first and Patent Owner should respond because neither party is seeking relief from the Board, as would be the case when a motion and opposition are filed.”) But some panels stagger the briefing, with the petitioner filing an opening brief and the patent owner filing a response a week later. See, e.g., Sipnet EU S.R.O. v. Straight Path IP Group, Inc., IPR2013-00246 (Mar, 29, 2016) (Paper 68) at 2.

No New Evidence

Ever since the first panel handled a remand in Microsoft Corp. v. Proxyconn, Inc., IPR2012-00026 (Sept. 1, 2015) (Paper 77) at 3, it appears that the PTAB has ordered that no new evidence may be filed with the briefs. However, the PTAB recently ordered briefing on whether new declaratory evidence would be appropriate.  SAS Inst., Inc. v. ComplementSoft, LLC, IPR2013-00226 (Dec. 15, 2016) (Paper 48) at 4. When citing evidence, the Board has ordered that the parties must provide citations to the existing record where the evidence originally was introduced.  See, e.g., Sipnet EU S.R.O. v. Straight Path IP Group, Inc., IPR2013-00246 (Mar. 29, 2016) (Paper 68) at 2.

Timing of New Final Written Decision

The PTAB often takes about 3-6 months from the date of the Federal Circuit’s mandate to issue its new final written decision on remand, although there are outliers. In the cases that have received a second final written decision, the results have been mixed, with the PTAB sometimes reversing and other times maintaining its findings from the original final written decision. In most remands, the PTAB has found that the petitioner did not show the reviewed claims to be unpatentable.

Chart Summarizing PTAB Remands

The chart below summarizes the procedural aspects of the cases that have been remanded to the PTAB.  When no comments are provided, that indicates there has been no reported activity on the docket:

  Date of Mandate How long after mandate for hearing Who requested hearing?  Order on Remand Briefing Final Decision Remand Results
Microsoft Corp. v. Proxyconn, Inc. IPR2012-00026 & IPR2013-00109US 6,757,717 8/25/2015 2 days Petitioner Paper 77 Simultaneous briefing; 15 pages Paper 80 12/8/2015
Sipnet EU S.R.O. v. Straight Path IP Group, Inc., IPR2013-00246US 6,108,704 1/14/16 7 weeks unknown Paper 68 Petitioner brief - 7 pages Patent Owner reply - 7 pages Page 73 5/23/2016 Reverse prior decision; not establish unpatentable
MotivePower, Inc. v. Cutsforth, Inc.,IPR2013-00274US 7,990,018 2/29/16 1 month unknown Paper 37 Simultaneous briefing; 5 pages Paper 44 9/9/16 Maintained most claims not patentable; Reversed prior decision -not establish unpatentable for some
Adidas AG v. Nike, Inc.,IPR2013-00067US 7,347,011 4/4/2016 4 months to order none Paper 62 No briefing since no party requested it    
Corning Optical Comm’ns RF, LLC v. PPC Broadband, Inc., IPR2013-00340IPR2013-00345IPR2013-00346IPR2013-00347US 8,323,060US 8,313,353US 8,287,320 4/15/2016 1 month to Order No hearing Paper 82 board orders parties to discuss whether there should be briefing PAper 85 Denied request for briefing Paper 89 11/16/2016 Maintained claims not patentable
Corning Optical Comm’ns RF, LLC v. PPC Broadband, Inc.,
IPR2013-00342
US 8,323,060
4/15/2016 1 month to Order   Paper 51 board orders parties to discuss whether there should be briefing Paper 55 Denied request for briefing Paper 57 10/12/2016 Reverse prior decision; not establish unpatentable
Ariosa Diagnostics, Inc. v. Verinata Health, Inc.,
IPR2013-00276 & IPR2013-00277
US 8,318,430
12/23/2015 3 weeks unknown Paper 49 Petitioner brief - 15 pages Patent Owner reply - 15 pages Paper 64 8/15/2016 Maintained not establish unpatentable
Dell, Inc. v, Acceleron, LLC, IPR2013-00440US 6,948,021 4/21/2016 3 weeks Both parties Paper 46 Simultaneous briefing; 10 pages Paper 49 8/22/2016 Reverse prior decision; not establish unpatentable
Shaw Indus. Group, Inc. v. Automated Creel Sys., Inc.,
IPR2013-00132
US 7,806,360
11/14/2016 1 month unknown Paper 48 Simultaneous briefing; 5 pages    
SAS Inst., Inc. v. ComplementSoft, LLC,
IPR2013-00226
US 7,110,936
11/14/2016 1 month unknown Paper 48 Simultaneous briefing; 5 pages    
Respironics, Inc. v. Zoll Medical Corp, IPR2013-00322
US 6,681,003
7/29/16 Fed. Cir. Decision         Parties filed joint motion to terminate on 11/21/16
Nuvasive, Inc. v. Warsaw Orthopedic, Inc., IPR2013-00206 & IPR2013-00208
US 8,251,997
9/30/2016 1.5 months   Paper 73 Patent Owner brief ; 10 pages; Petitioner no longer a party    
Veeam Software Corp. v. Symantec Corp.,IPR2014-00090
US 7,024,527
8/30/16 Fed. Cir. Decision          
Neste Oil Oyj, v. REG Synthetic Fuels, LLC, IPR2013-00578
US 8,231,804
11/9/16 Fed. Cir. Decision          
Medtronic, Inc. v. Nuvasive, Inc., IPR2013-00507 & IPR2013-00508US 8,187,334 11/9/16 Fed. Cir. Decision          
Olympus America, Inc. v. Perfect Surgical Techniques, Inc.,
IPR2014-00233
US 6,030,384
11/15/16 Fed. Cir. Decision          
Google Inc. v. Unwired Planet, LLC,
CBM2014-00006
US 7,203,752
11/21/2016  

 

Tags

United States Court of Appeals for the Federal Circuit (CAFC), remand

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Anthony A. Hartmann
Of Counsel
Washington, DC
+1 202 408 4275
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP